Please use this identifier to cite or link to this item:
Title: Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.
Issue Date: 1-Dec-2017
Citation: Ann. Oncol..2017 Dec;(28)12:2932-2942
Abstract: Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial growth factor receptor 2, has been approved for treating gastric/gastroesophageal junction, non-small-cell lung, and metastatic colorectal cancers. With the completion of six global, randomized, double-blind, placebo-controlled, phase III trials across multiple tumor types, an opportunity now exists to further establish the safety parameters of ramucirumab across a large patient population.
PMID: 28950290
Rights: openAccess
Appears in Collections:Hospitales > H. U. 12 de Octubre > Artículos

Files in This Item:
File Description SizeFormat 
PMC5834052.pdf388.79 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.